<DOC>
	<DOCNO>NCT02086006</DOCNO>
	<brief_summary>This prospective , consecutive enrolment , single-arm study enroll 15 patient single de novo , Type A lesion &lt; 10 mm length locate native coronary artery reference vessel diameter 2.75 mm - 3.0 mm measure offline QCA IVUS . All patient receive 3.0 x 14mm DESolve Stent load approximately 40 mcg Myolimus . - Angiographic intravascular ultrasound ( IVUS ) complete patient baseline 6 month . - Optical Coherence Tomography ( OCT ) complete patient baseline 6 month . - Multi-slice computed tomography ( MSCT ) conduct patient enrol 12 24 month .</brief_summary>
	<brief_title>Elixir Medical Clinical Evaluation DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient must least 18 year age Patient able verbally confirm understand risk , benefit treatment alternative receive DESolve Myolimus Eluting BCSS he/she his/her legally authorize representative provide write informed consent , approve appropriate Ethics Committee respective clinical site , prior clinical study related procedure Patient must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study electrocardiogram ( ECG ) change consistent ischemia ) Patient must acceptable candidate coronary artery bypass graft ( CABG ) surgery Patient must agree undergo clinical study require followup visit , angiogram , IVUS , OCT MSCT Patient must agree participate clinical study period two year follow index procedure Patients know diagnosis acute myocardial infarction ( AMI ) within 72 hour precede index procedure CK CKMB return within normal limit time procedure The patient currently experience clinical symptom consistent AMI Patient current unstable arrhythmia Patient undergone previous percutaneous intervention lesion either nontarget vessel target vessel Patient undergone previous percutaneous intervention lesion either nontarget vessel target vessel Patient known leave ventricular ejection fraction ( LVEF ) &lt; 30 % Patient receive heart transplant organ transplant wait list organ transplant Patient receiving schedule receive chemotherapy malignancy within 30 day prior procedure Patient receive immunosuppression therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus etc . ) Patient receive schedule receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) Patient know hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , Myolimus , PLLA polymer contrast sensitivity adequately premedicated Elective surgery plan within first 6 month procedure require discontinue either aspirin clopidogrel Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease . Patient known renal insufficiency ( e.g. , serum creatinine level 2.5 mg/dL , patient dialysis ) Patient history bleed diathesis coagulopathy refuse blood transfusion Patient cerebrovascular accident ( CVA ) transient ischemic neurological attack ( TIA ) within past six month Patient significant GI urinary bleed within past six month Patient extensive peripheral vascular disease precludes safe 7 French sheath insertion Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance clinical study plan , confound data interpretation associate limited life expectancy ( i.e. , less one year ) Patient already participate another clinical study Women childbearing potential undergone surgical sterilization postmenopausal ( define amenorrheic least one year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary artery disease</keyword>
</DOC>